The present disclosure relates generally to new cannabis plants, including parts, extracts and uses thereof, comprising a cannabinoid profile enriched for total THC (i.e., Δ-9-tetrahydrocannabinol (THC) and Δ-9-tetrahydrocannabinolic acid (THCA), total CBG (i.e., cannabigerol (CBG) and cannabigerolic acid (CBGA)), and total THCV (i.e., tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA)).

The present application relates to a compositions and methods comprising or expressing a MOMO30 protein derived from Momordica balsamina. The MOMO30 protein is about 30 kDa in size, binds coronavirus S protein, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding to coronavirus spike (S) protein, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by a coronavirus or alleviating symptoms in coronavirus infected patients and comprises the amino acid sequence of SEQ ID NO: 1. The MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for preventing or treating viral infections by coronaviruses and others.

The present application relates to an anti-coccidial composition comprising mangosteen, and the uses thereof. The composition comprising mangosteen according to an example has excellent effect of directly killing protozoa which can induce coccidiosis, effect of inhibiting cell penetration by protozoa and/or effect of inhibiting intracellular protozoan proliferation, and has excellent in vivo coccidiosis prevention, relief and therapeutic effects.

A transmucosal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transmucosal psychoactive alkaloid composition also includes a mucoadhesive polymer, a carrier, and optional further excipients. The non-ingestive composition may be taken orally through the mucosa. A process for obtaining an oral transmucosal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid and standardizing to a specific concentration by adding measured quantities of excipients.

A raw cannabis powder is formed and packaged for convenient and low-cost access to raw cannabis. First, raw cannabis material having a pre-determined ratio of cannabinoids is collected. Next, the raw cannabis material is dried. Next, the dried raw cannabis material is grinded to obtain a finely ground powder. Next, the raw cannabis powder is packaged into a container. High concentrate cannabis extract is optionally added to increase potency of cannabinoids. Instructions are provided that instruct a consumer on amounts and types of cannabinoids, dosing and serving sizes for consuming the powder in its raw non-decarboxylated form, dosing and serving sizes for a decarboxylated (heated) version of the powder, and how to decarboxylate the cannabinoids within the powder. A consumer purchases the container of raw cannabis powder and adds the raw cannabis powder to food or beverages, consumes the powder directly, or decarboxylates the powder and consumes the decarboxylated powder.

Novel fragrant and flavorful Cannabis plant products with defined chemistry customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.

Novel plant products customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.

Novel plant products customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.

The present invention relates to Labisia pumila extract composition for reducing the progression of health problems and process for preparation thereof and their uses. More particularly, the present invention relates to corresponding process and to certain novel compounds of Labisia pumila extract composition for pharmaceutical formulation. One of the advantages of process of the extraction is having shorter duration extraction compared to the prior art documents. In addition, the Labisia pumila extract can be stored up to 3 years shelf-life with improved stability in storage, including shelf-life and their useable administration. Another advantage of the pharmaceutical formulation of the present invention is an improved formulation with pharmaceutical grade safety standard, and its optimised and stable pharmaceutical dosage form for clinical use and reducing the progression of health problems selected from obesity, metabolic syndrome, anti-inflammatory and anti-oxidant treatment.

Disclosed is a method for preparing bitter Ganoderma lucidum spore powder, and relates to the field of drugs or health care products. The method includes: removing visible impurities from Ganoderma lucidum spores, conducting ice bath and heating extraction, filtering through a microfiltration membrane, sterilizing by drying, and conducting sporoderm disruption to obtain the bitter Ganoderma lucidum spore powder. The preparation method effectively improves the content of the bitter substances in the Ganoderma lucidum spore powder by removing shriveled spores through multiple times of impurity removal and filtration in combination with the manner of conducting sporoderm disruption after extraction. Taking the total Ganoderma lucidum triterpenoids in the Ganoderma lucidum spores as a representative of the bitter substances, the content of the total Ganoderma lucidum triterpenoids can reach 5-8%. Meanwhile, the preparation method can also make the content of Ganoderma lucidum polysaccharides reaching 6-10%.